Centogene
Centogene Strikes Rare Disease Target Discovery Deal With Insilico Medicine
The companies aim to identify therapeutic targets for Niemann-Pick disease type C, a rare genetic lysosomal storage disorder.
Centogene Reports 17 Percent Drop in Q3 Revenues, Closing Down COVID Testing Business
Given its dwindling cash position, the firm will phase out its COVID-19 testing business and streamline its footprint, resulting in up to €15 million in cost savings per year.
Twist Bioscience, Centogene Partner on NGS-Based Rare Disease Genetic Testing
The partners will design multiple assay kits in an attempt to make genetic testing for rare diseases more accessible to patients.
Sequencing Study Points to Prenatal Development Syndrome, Possible Treatment Strategy
With the help of sequencing, researchers identified several families affected by Zaki syndrome, caused by potentially targetable mutations affecting Wnt signaling.
Dec 16, 2020
Centogene Q3 Revenues Triple on COVID-19 Testing
Sep 23, 2020
Centogene Reports 13 Percent Decline in Q2 Revenues
Jul 10, 2020
Centogene to Raise $28M in Public Stock Offering
Jun 15, 2020